Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Moderna Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $21.1B |
|---|
| Revenue (ttm) | 2.2B |
|---|
| Net income (ttm) | -3.2B |
|---|
| EPS (ttm) | -$8.01 |
|---|
| Shares out | 399.2M |
|---|
| Volume | 10,987,308 |
|---|
| Beta | 1.09 |
|---|
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $17.74B | $18.88B | $6.75B | $3.20B | $1.92B | -42.6% |
| Gross profit | $15.12B | $13.46B | $2.06B | $1.74B | $1.05B | -48.6% |
| Operating income | $13.30B | $9.42B | $-4.24B | $-3.58B | $-2.76B | — |
| Net income | $12.20B | $8.36B | $-4.71B | $-3.56B | $-2.82B | — |
| EPS (diluted) | $28.29 | $20.12 | $-12.33 | $-9.28 | — | — |
| EBITDA | $13.53B | $9.77B | $-3.62B | $-3.39B | $-2.54B | — |
| R&D | $1.99B | $3.30B | $4.85B | $4.54B | $3.13B | +12.0% |
| SG&A | $567.0M | $1.13B | $1.55B | $1.17B | $1.02B | +15.8% |
Recent company headlines from major financial publishers.
The mRNA platform's speed and adaptability result in best-in-class efficacy for multiple latent virus and oncology targets. MRNA establishes a broad, highly profitable commercial portfolio, driving revenues back toward $10B+ with 70%+ gross margins and substantial operating leverage.
Moderna undergoes a high-risk transition, absorbing multi-billion dollar operating losses to sustain its $3.1B R&D engine. The validated mRNA platform produces sufficient new blockbusters to return to revenue growth and reach steady-state profitability by the end of the decade.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 7.5% | $68.8 | $75.7 | $84.0 | $94.5 | $102 |
| 8.5% | $58.3 | $63.1 | $68.8 | $75.7 | $84.0 |
| 9.5% | $50.6 | $54.2 | $58.3 | $63.1 | $68.8 |
| 10.5% | $44.6 | $47.4 | $50.6 | $54.2 | $58.3 |
| 11.5% | $40.0 | $42.2 | $44.6 | $47.4 | $50.6 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
